BLINCYTO® is the world’s first approved BiTE® immuno-oncology therapy, targeting the CD19 surface antigen on B cells. BiTE® molecules help the immune system detect and target malignant cells by bringing T cells—a type of white blood cell capable of killing cells recognized as threats—into contact with cancer cells. By positioning T cells near cancer cells, they can...